Free Trial
NASDAQ:INNV

InnovAge (INNV) Stock Price, News & Analysis

InnovAge logo
$4.08 -0.32 (-7.27%)
(As of 12/17/2024 ET)

About InnovAge Stock (NASDAQ:INNV)

Key Stats

Today's Range
$4.05
$4.47
50-Day Range
$4.40
$6.30
52-Week Range
$3.52
$6.69
Volume
95,424 shs
Average Volume
38,849 shs
Market Capitalization
$552.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Reduce

Company Overview

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.

InnovAge Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
29th Percentile Overall Score

INNV MarketRank™: 

InnovAge scored higher than 29% of companies evaluated by MarketBeat, and ranked 828th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    InnovAge has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    InnovAge has only been the subject of 2 research reports in the past 90 days.

  • Read more about InnovAge's stock forecast and price target.
  • Earnings Growth

    Earnings for InnovAge are expected to grow in the coming year, from ($0.06) to $0.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InnovAge is -34.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InnovAge is -34.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    InnovAge has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.48% of the float of InnovAge has been sold short.
  • Short Interest Ratio / Days to Cover

    InnovAge has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in InnovAge has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    InnovAge does not currently pay a dividend.

  • Dividend Growth

    InnovAge does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.48% of the float of InnovAge has been sold short.
  • Short Interest Ratio / Days to Cover

    InnovAge has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in InnovAge has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • News Sentiment

    InnovAge has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for InnovAge this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, InnovAge insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.40% of the stock of InnovAge is held by insiders.

  • Percentage Held by Institutions

    Only 12.26% of the stock of InnovAge is held by institutions.

  • Read more about InnovAge's insider trading history.
Receive INNV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InnovAge and its competitors with MarketBeat's FREE daily newsletter.

INNV Stock News Headlines

Trump’s Secret Manhattan Project
On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.
See More Headlines

INNV Stock Analysis - Frequently Asked Questions

InnovAge's stock was trading at $6.00 on January 1st, 2024. Since then, INNV stock has decreased by 32.0% and is now trading at $4.08.
View the best growth stocks for 2024 here
.

InnovAge Holding Corp. (NASDAQ:INNV) announced its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). The business earned $205.14 million during the quarter, compared to the consensus estimate of $203.35 million. InnovAge had a negative trailing twelve-month return on equity of 5.68% and a negative net margin of 2.03%.

InnovAge (INNV) raised $301 million in an initial public offering on Thursday, March 4th 2021. The company issued 16,700,000 shares at $17.00-$19.00 per share. J.P. Morgan, Barclays, Goldman Sachs and Citigroup served as the underwriters for the IPO and Baird, William Blair, Piper Sandler, Capital One Securities, Loop Capital Markets, Siebert Williams Shank and Roberts & Ryan were co-managers.

Top institutional shareholders of InnovAge include Geode Capital Management LLC (0.39%), State Street Corp (0.25%), Charles Schwab Investment Management Inc. (0.12%) and Barclays PLC (0.02%).
View institutional ownership trends
.

Shares of INNV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that InnovAge investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/05/2024
Today
12/18/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Health services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:INNV
Fax
N/A
Employees
2,350
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$7.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+47.1%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-21,340,000.00
Pretax Margin
-2.08%

Debt

Sales & Book Value

Annual Sales
$786.51 million
Book Value
$2.04 per share

Miscellaneous

Free Float
133,559,000
Market Cap
$552.66 million
Optionable
Optionable
Beta
0.31

This page (NASDAQ:INNV) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners